Filiation

REMAR-IVECAT Group, "Germans Trias i Pujol" Health Sciences Research Institute (IGTP) & Nephrology Service, "Germans Trias i Pujol" Univ. Hospital (HUGTiP), Can Ruti Campus, Badalona, Barcelona, Spain;

Biosketch

Dr. Francesc E. Borràs graduated in Biology at the University of Barcelona in 1991. His phD studies were supervised by Drs. Antonio Celada and Jorge LLoberas, and focused on cellular and molecular aspects of macrophages. In 1998 he joined the Dept. of Histocompatibility and Immunogenetics at the National Blood Service in London (UK) led by Dr. Cristina Navarrete, where he started to work on DC’s biology in tolerance as a post-doctoral fellow. In 2002, he earned a junior “Miguel Servet” researcher position and joined the Immunology lab at the “Germans Trias i Pujol” Research Institute (IGTP), directed by Dr. Ricardo Pujol, where he founded and led the Dendritic Cells´ research group (DCTeam).

After completing the “Miguel Servet” program in 2008, he was further promoted to a Senior Researcher position by the “Instituto de Salud Carlos III” and the “Generalitat de Catalunya” (Dept. of Health), and founded the IVECAT Group at the IGTP. Since 2014, Dr. Borràs is coordinator of the Research Group REMAR (from “Recerca en Malalties d’Afectació Renal”), a research group funded by “Generalitat of Catalonia” (2014SGR804), which includes health professionals with an interest in studying and addressing the problems of kidney diseases.

Over the past 10 years, the group has maintained two lines of research focusing respectively on the induction of tolerance and in extracellular vesicles or exosomes. Dr. Borràs has led and supervised several research projects and doctoral thesis, and participated in the publication of over 50 manuscripts.

Dr. Borràs has been member of the board of the Catalan Society for Immunology (2008-12), assistant professor of Immunology at the UAB (2004-2012) and Chief Editor of “Revista Inmunología” (2010-13).

He is currently member of the Editorial Board of the “Journal of Extracellular Vesicles”, member of ISEV (International Society for Extracellular Vesicles) and joint member of the Management Committee of the COST ME-HAD action (http://www.mehad-cost.eu). Dr. Borràs is also co-founder and vice president of GEIVEX (Spanish Research Group on Extracellular Vesicles, geivex.org) and co-founder of “Innovex Therapeutics”, a spin-off devoted to harness clinical application of extracellular vesicles.

Research interests

Extracellular Vesicles are envisaged as a potential breakthrough in biomedicine. Their role in different aspects of cell biology make them attractive for strategies from biomarker discovery to vaccination. Our current aim in the laboratory is harnessing EVs as feasible biomarkers for pathologies that are currently miss-diagnosed or require invasive techniques for precise diagnosis. Moreover, we also aim to study the interaction/participation and potential role of EVs in the immune response with the aim to induce transplantation tolerance.

Top